Please login to the form below

psoriatic arthritis

This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.

J&J's Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market. Johnson &Johnson has submitted an application to the FDA for the approval of Tremfya in psoriatic arthritis, which could further congest an intensely competitive ... This includes Novartis’

Latest news

Novartis eyes potential new indication for Cosentyx

ray. It is also approved for the treatment of psoriatic arthritis and psoriasis.
FDA clears Lilly’s Taltz for ankylosing spondylitis

Taltz (ixekizumab) – an interleukin-17 inhibitor previously approved for psoriasis and psoriatic arthritis – now has the same diseases on its label as class leader Cosentyx (secukinumab) which grew by almost a ... Skyrizi has been approved for
Amgen snaps up Celgene’s Otezla for $13.4bn

Otezla is currently approved for three indications in the US - moderate-to-severe plaque psoriasis (in patients eligible for phototherapy or systemic therapy), adults with active psoriatic arthritis; and the recently
Triplet approvals for myeloma boost Celgene in Q2

Otezla buoyant. Meanwhile, Celgene’s other big product – Otezla (apremilast) for psoriasis, psoriatic arthritis and latterly Behçet’s disease – had another spectacular quarter with a 31% gain to $493m, just as
Gilead strikes $5.1bn deal to bolster ties with Galapagos

rheumatoid arthritis. ... Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s

More from news
Approximately 14 fully matching, plus 114 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular
Drug launches to watch in 2019

Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
The good, the bad and the ugly

Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
Deal Watch December 2016

510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small
Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Changing healthcare, one film at a time

Millefeuille’ [ IMDB] explores the issues of isolation and restriction people with psoriasis and psoriatic arthritis struggle with, and the degree to which they are self-imposed, through the character of Élodie –
emotive adds to medical team with new Scientific Lead and Associate Medical Writer

Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
Lucid win PMEA Support Agency of the Year 2016

management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016

um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
Millefeuille

This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager – Healthcare advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...